Bioatla Total Revenue Over Time
| BCAB Stock | USD 1.18 0.13 9.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bioatla Performance and Bioatla Correlation. Bioatla |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share 0.228 | Quarterly Revenue Growth 0.316 | Return On Assets (0.50) | Return On Equity (1.39) |
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioatla is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Revenue Analysis
Compare Bioatla and related stocks such as Pmv Pharmaceuticals, C4 Therapeutics, and Nautilus Biotechnology Total Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCCC | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 21.4 M | 33.2 M | 45.8 M | 31.1 M | 20.8 M | 31.5 M |
| NAUT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| IPSC | 950.8 M | 950.8 M | 950.8 M | 950.8 M | 950.8 M | 950.8 M | 470.3 M | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 M | 5.2 M | 2.2 M | 2.1 M |
| PASG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| IKNA | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 9.2 M | 31 M | 15.6 M | 9.2 M | 12.6 M |
| OLMA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| AVTE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ADAG | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 480 K | 480 K | 10.2 M | 9.3 M | 18.1 M | 19 M |
| ACRV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| RZLT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ANTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ERAS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| STTK | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 9.9 M | 9.9 M | 30 M | 652 K | 1.7 M | 1.6 M |
| KYMR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.9 M | 34 M | 72.8 M | 46.8 M | 78.6 M | 43.1 M |
| NRIX | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 31.1 M | 17.8 M | 29.8 M | 38.6 M | 77 M | 88.5 M | 93 M |
Bioatla and related stocks such as Pmv Pharmaceuticals, C4 Therapeutics, and Nautilus Biotechnology Total Revenue description
Total revenue comprises all receipts Bioatla generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.My Equities
My Current Equities and Potential Positions
| Bioatla | BCAB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.18
Check out Bioatla Performance and Bioatla Correlation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Bioatla technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.